Pasithea Therapeutics Shares Outstanding vs. Cash And Equivalents

KTTA Stock  USD 2.73  0.06  2.15%   
Based on Pasithea Therapeutics' profitability indicators, Pasithea Therapeutics Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Pasithea Therapeutics' ability to earn profits and add value for shareholders. As of December 29, 2024, Price To Sales Ratio is expected to decline to 36.39. In addition to that, EV To Sales is expected to decline to -31.1. At present, Pasithea Therapeutics' Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Income Tax Expense is expected to grow to about 476.6 M, whereas Accumulated Other Comprehensive Income is forecasted to decline to (4.9 K).
For Pasithea Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pasithea Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pasithea Therapeutics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pasithea Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pasithea Therapeutics Corp over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(14.79)
Revenue Per Share
0.37
Quarterly Revenue Growth
14.981
Return On Assets
(0.38)
Return On Equity
(0.63)
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pasithea Therapeutics Cash And Equivalents vs. Shares Outstanding Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pasithea Therapeutics's current stock value. Our valuation model uses many indicators to compare Pasithea Therapeutics value to that of its competitors to determine the firm's financial worth.
Pasithea Therapeutics Corp is rated below average in shares outstanding category among its peers. It is rated fifth overall in cash and equivalents category among its peers creating about  37.85  of Cash And Equivalents per Shares Outstanding. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pasithea Therapeutics' earnings, one of the primary drivers of an investment's value.

Pasithea Cash And Equivalents vs. Shares Outstanding

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Pasithea Therapeutics

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
1.27 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Pasithea Therapeutics

Cash

 = 

Bank Deposits

+

Liquidities

 = 
47.94 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Pasithea Cash And Equivalents Comparison

Pasithea Therapeutics is currently under evaluation in cash and equivalents category among its peers.

Pasithea Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pasithea Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pasithea Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Pasithea Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Pasithea Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-4.7 K-4.9 K
Operating Income-16 M-15.2 M
Income Before Tax-15.5 M-14.7 M
Total Other Income Expense Net471.6 K733.3 K
Net Loss-2 M-1.9 M
Net Loss-15.5 M-14.7 M
Income Tax Expense453.9 M476.6 M
Net Interest Income242.4 K254.6 K
Net Loss-16.7 M-17.6 M
Interest Income415.4 K228.5 K
Change To Netincome-1 M-1.1 M
Net Loss(12.65)(13.28)
Net Income Per E B T 1.03  0.79 

Pasithea Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pasithea Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pasithea Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pasithea Therapeutics' important profitability drivers and their relationship over time.

Use Pasithea Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pasithea Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pasithea Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Pasithea Therapeutics Pair Trading

Pasithea Therapeutics Corp Pair Trading Analysis

The ability to find closely correlated positions to Pasithea Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pasithea Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pasithea Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pasithea Therapeutics Corp to buy it.
The correlation of Pasithea Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pasithea Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pasithea Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pasithea Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Pasithea Therapeutics position

In addition to having Pasithea Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Wireless Thematic Idea Now

Wireless
Wireless Theme
Companies providing wireless technology and communication services. The Wireless theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wireless Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:
Check out Correlation Analysis.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
To fully project Pasithea Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pasithea Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pasithea Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Pasithea Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Pasithea Therapeutics investors may work on each financial statement separately, they are all related. The changes in Pasithea Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pasithea Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.